Pharmaceutical

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

The FDA has approved BeiGene’s Tevimbra with chemotherapy for treating oesophageal squamous cell carcinoma.

Mar 5, 2025 - 06:00
FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
The FDA has approved BeiGene’s Tevimbra with chemotherapy for treating oesophageal squamous cell carcinoma.
Read the original article

Tags:

Previous Article

MWC Barcelona 2025: Maximizing 5G network value in the age of AI

Next Article

Antibody drug conjugates: Tackling the unsolved challenges with novel technologies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pandemic-related immunity gap in kids explains surge of respiratory infections in children in China, says WHO

Pandemic-related immunity gap in kids explains surge of...

Nov 25, 2023

Container Closure Integrity Testing (CCIT): How to get started with deterministic methods

Container Closure Integrity Testing (CCIT): How to get ...

Mar 29, 2023

EMA CHMP provides positive opinion for ViiV’s cabotegravir

EMA CHMP provides positive opinion for ViiV’s cabotegravir

Jul 25, 2023